Merck reports positive results from pivotal phase 3 trials of once-daily, oral, two-drug, single ...

Merck announced positive phase 3 trial results for doravirine/islatravir, a once-daily, oral, two-drug regimen for HIV-1, showing non-inferiority to current therapies. The company plans to present findings and file with regulators, continuing its commitment to advancing HIV treatment options.